HPSE and breast carcinoma: M402 is a rationally engineered, non-cytotoxic HS mimetic, designed to inhibit multiple factors implicated in tumor–host cell interactions, including VEGF, FGF2, SDF1α, P-selectin, and heparanase demonstrating anti-metastatic activity alone and in combination with cisplatin or docetaxel in the orthotropic 4T1 murine mammary carcinoma model (154).